Table 3.
Expression of MGMT, ERCC 1 , hMSH 2 , and hMLH 1 in ductal adenocarcinoma and non-cancerous pancreatic tissues (%)
| Group | n | MGMT | ERCC 1 | hMSH 2 | hMLH 1 |
|---|---|---|---|---|---|
| Pancreatic ductal adenocarcinoma |
|
||||
| A + B |
28 |
15 (53.6) |
13 (46.2) |
14 (50.0) |
12 (42.9) |
| A |
17 |
9 (52.9) |
8 (47.1) |
9 (52.9) |
8 (47.1) |
| B |
11 |
6 (54.6) |
5 (45.5) |
5 (45.5) |
4 (36.4) |
| Non-cancerous pancreatic tissues |
|
||||
| A + B |
43 |
35 (81.4) |
33 (76.7) |
32 (74.4) |
30 (70.0) |
| A |
19 |
14 (73.7) |
14 (73.7) |
12 (63.2) |
11 (57.9) |
| B | 24 | 21 (87.5) | 19 (79.2) | 19 (79.2) | 19 (79.2) |
Pancreatic ductal adenocarcinoma compared with non-cancerous pancreatic tissues in group A + B: χ2MGMT = 6.30, P <0.05; χ2ERCC1 = 6.83, P <0.01; χ2hMSH2 = 4.43, P <0.05; χ2hMLH1 = 5.08, P <0.05.
Pancreatic ductal adenocarcinoma compared with non-cancerous pancreatic tissues in group A: PMGMT = 0.157, PERCC1 = 0.088, PhMSH2 = 0.103, PhMLH1 = 0.452.
Pancreatic ductal adenocarcinoma compared with non-cancerous pancreatic tissues in group B: PMGMT = 0.042, PERCC1 = 0.050, PhMSH2 = 0.050, PhMLH1 = 0.018.